A Multicenter, Randomized, Double-blind, Placebo-controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 主要终点
- Percent change from baseline in the frequency of motor seizures involving the trunk or extremities [tonic, atonic, generalized tonic-clonic (GTC), focal seizures with motor components (FSMC)]
研究概览
简要总结
This Phase 3 trial will enroll participants diagnosed with Lennox-Gastaut Syndrome (LGS) who are still experiencing at least 4 motor seizures involving the trunk or extremities per week, despite ongoing treatment with up to 3 antiepileptic drugs (AEDs) and who meet inclusion/exclusion criteria.
Following a 28-day baseline period, participants will begin an 84-day treatment period. Participants will be assigned to receive twice daily doses of placebo or cannabidiol oral solution at the highest dose determined to be safe in a previous trial.
Following study completion, all participants will be invited to receive Cannabidiol Oral Solution in an open label extension study (under a separate protocol).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 2 Years 至 30 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Meets protocol-specified criteria for qualification and contraception, including clinical diagnosis of refractory LGS and onset of seizures according to protocol-specified criteria
- •Is able to speak and understand the language in which the study is being conducted, is able to understand the procedures and study requirements and has voluntarily signed and dated an informed consent form approved by the Institutional Review Board before the conduct of any study procedure
- •In the opinion of the Investigator, the participants and parent(s)/caregiver(s) are willing and able to comply with the study procedures and visit schedules, including venipuncture, twice daily dosing, accurate diaries, and the Follow-up Visits (if applicable).
排除标准
- •Medical history is outside protocol-specified parameters
- •Clinically significant history of allergic reactions or significant sensitivities to cannabinoids or to any of the other ingredients in the study drug
- •Inadequate supervision by parents or guardians
- •History or current use of dietary supplements, drugs or over-the counter medications outside protocol-specified parameters
- •Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or well-being of the participant or study staff; 2) the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3) the analysis of results
研究组 & 干预措施
Placebo Solution
Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
干预措施: Placebo Solution (Drug)
Cannabidiol Oral Solution
Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
干预措施: Cannabidiol Oral Solution (Drug)
结局指标
主要结局
Percent change from baseline in the frequency of motor seizures involving the trunk or extremities [tonic, atonic, generalized tonic-clonic (GTC), focal seizures with motor components (FSMC)]
时间窗: Data point for observation period to data point for treatment period Weeks 9 through 12
次要结局
- Percent change from baseline in severity of motor seizures involving the trunk or extremities (tonic, clonic, GTC, FSMC)(Data point for observation period to data point for treatment period Weeks 9 through 12)
- Percent change from baseline in frequency of all seizure activity independent of seizure type(Data point for observation period to data point for treatment period Weeks 9 through 12)
- Percent change from baseline in the severity of all seizure activity independent of seizure type(Data point for observation period to data point for treatment period Weeks 9 through 12)
- Percent change from baseline in the duration of all seizure activity independent of seizure type(Data point for observation period to data point for treatment period Weeks 9 through 12)
- Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Improvement (CGI-I)(Data point for observation period to data point for treatment period Weeks 9 through 12)
- Change from baseline in Investigator CGI-I(Data point for observation period to data point for treatment period Weeks 9 through 12)
- Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Severity (CGI-S)(Data point for observation period to data point for treatment period Weeks 9 through 12)
- Change from baseline in Investigator CGI-S(Data point for observation period to data point for treatment period Weeks 9 through 12)